Hideki Shima

Chief Financial Officer (CFO)

Therapeutic Areas

Drug	Indication	Phase
Zolbetuximab	CLDN18.2-positive gastric/GEJ adenocarcinoma	Phase 3
Fezolinetant	Vasomotor symptoms due to menopause	Approved
AT845	Late-Onset Pompe Disease	Phase 1/2
AT466	X-Linked Myotubular Myopathy (XLMTM)	Phase 1/2
ASP2138	Gastric/GEJ cancer, Pancreatic cancer	Phase 1/2
ASP3082	Solid tumors with KRAS G12D mutation	Phase 1
ASP5354	Ureter identification during surgery	Phase 3
Rozanolixizumab	Generalized Myasthenia Gravis	Approved